Sonus Pharmaceuticals has submitted a New Drug Application with the US authorities for EchoGen (perflenapent emulsion), the first fluorocarbon-based ultrasound contrast agent. The product was developed to enhance the clinical utility and cost-effectiveness of ultrasound procedures in radiology and cardiology.
Pivotal Phase III echocardiography and radiology clinical trials with EchoGen were conducted in 410 patients in 33 study sites in the USA. The NDA filing triggers a $4 million milestone payment from Abbott Laboratories, which has rights to market the product in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze